Table 1.
Patient and Disease Characteristics (N = 245)
| Patient Characteristic | No. of Patients |
| INSS neuroblastoma disease stage | |
| 4 | 243 |
| 3 | 2 |
| Age, years | |
| < 1.5 | 21 |
| > 1.5 | 224 |
| MYCN status | |
| Nonamplified | 142 |
| Amplified | 77 |
| Unknown | 26 |
| LDH, U/mol | |
| < 1,500 | 128 |
| > 1,500 | 66 |
| Unknown | 51 |
| Bone marrow metastases | |
| No | 24 |
| Yes | 221 |
| Bone metastases | |
| No | 56 |
| Yes | 189 |
| Disease status at 3F8 therapy | |
| First CR/VGPR | 108 |
| Second CR/VGPR | 19 |
| Primary refractory | 86 |
| Secondary refractory | 4 |
| Other* | 26 |
| KIR3DL1 status | |
| Positive | 230 |
| Negative† | 15 |
| Treatment regimen | |
| ASCT + 3F8 | 168 |
| 3F8 alone | 77 |
Abbreviations: ASCT, autologous stem cell transplantation; CR, complete response; INSS, International Staging System for Neuroblastoma; LDH, lactate dehydrogenase; VGPR, very good partial response.
*
Patients who received 3F8 in combination with induction chemotherapy.
†
KIR3DL1-negative patients were considered homozygous for KIR3DS1.